Vident Investment Advisory’s Myriad Genetics MYGN Stock Holding History

Vident Investment Advisory’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,008	Closed	-$325K	–	1297
2023 Q1	$325K	Buy	+14,008	New	+$284K	0.01%	925
2022 Q1	–	Sell	-7,374	Closed	-$204K	–	1323
2021 Q4	$204K	Buy	+7,374	New	+$214K	0.01%	1130
2021 Q3	–	Sell	-6,689	Closed	-$205K	–	1204
2021 Q2	$205K	Buy	+6,689	New	+$193K	0.01%	1051
2018 Q3	–	Sell	-86,231	Closed	-$3.22M	–	977
2018 Q2	$3.22M	Buy	86,231 +1,293	+2%	+$43.7K	0.13%	212
2018 Q1	$2.46M	Sell	84,938 -30,183	-26%	-$1.02M	0.1%	283
2017 Q4	$3.95M	Buy	115,121 +7,029	+7%	+$237K	0.18%	101
2017 Q3	$3.91M	Sell	108,092 -46,975	-30%	-$1.34M	0.21%	81
2017 Q2	$4.01M	Buy	155,067 +2,641	+2%	+$56.1K	0.33%	65
2017 Q1	$2.93M	Buy	+152,426	New	+$2.7M	0.29%	80
2016 Q3	–	Sell	-50,802	Closed	-$1.55M	–	441
2016 Q2	$1.55M	Sell	50,802 -49,080	-49%	-$1.71M	0.22%	242
2016 Q1	$3.74K	Buy	99,882 +51,065	+105%	+$1.92M	0.23%	221
2015 Q4	$2.11M	Buy	48,817 +29,128	+148%	+$1.23M	0.27%	169
2015 Q3	$738K	Buy	19,689 +2,908	+17%	+$103K	0.1%	307
2015 Q2	$570K	Buy	16,781 +908	+6%	+$30.9K	0.08%	416
2015 Q1	$562K	Buy	15,873 +1,826	+13%	+$65.4K	0.11%	334
2014 Q4	$478K	Buy	+14,047	New	+$498K	0.16%	265

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Vident Investment Advisory's MYGN Position: Q2 2023 in Review

Vident Investment Advisory sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 14,008 shares — an estimated $325K sold.

Vident Investment Advisory first reported a position in MYGN in Q4 2014 and held it in 16 quarters. The position peaked at $4.01M in Q2 2017. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

Vident Investment Advisory reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
Vident Investment Advisory sold 14,008 Myriad Genetics shares in Q2 2023, an estimated $325K.
Vident Investment Advisory first reported a position in Myriad Genetics in Q4 2014 and held it in 16 quarters.
Vident Investment Advisory's Myriad Genetics position peaked at $4.01M in Q2 2017.
188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.